论文部分内容阅读
因为安全性问题饱受争议的药品近年来屡见不鲜。血管紧张素II受体阻滞剂(ARB)类药物近日也被掀到了风口浪尖。虽说对ARB类药物提出癌症风险质疑的荟萃分析存在诸多局限,结论的可
Drugs that have become controversial because of safety issues are not uncommon in recent years. Angiotensin II receptor blocker (ARB) drugs have recently been pushed to the cusp. Although there are many limitations on meta-analysis of the cancer risk posed by ARBs, the conclusions may be